HIV gene therapy - Adaptimmune/Cardiff University/University of Pennsylvannia

Drug Profile

HIV gene therapy - Adaptimmune/Cardiff University/University of Pennsylvannia

Alternative Names: SLYNTVATL

Latest Information Update: 16 Jul 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Adaptimmune; Cardiff University; University of Pennsylvania
  • Developer Adaptimmune; University of Pennsylvania
  • Class Cell therapies; Gene therapies
  • Mechanism of Action CD8 positive T lymphocyte stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • No development reported HIV infections

Most Recent Events

  • 16 Jul 2016 No recent reports of development identified for phase-I development in HIV-infections in USA (IV, Infusion)
  • 01 Jan 2014 Adaptimmune completes a phase I trial in HIV infections in USA (NCT00991224)
  • 01 Nov 2009 Phase-I clinical trials in HIV infections in USA (IV)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top